知镜 Cognispect · 医学文献与研究工作台

A phase 1, first-in-human study of safimaltib, a MALT1 inhibitor, in B-lymphocytic malignancies.

Hertzberg M, Cheah CY, Opat S, Kalac M, Abrisqueta P, Ribrag V, Bachy E, Ysebaert L, Qiu L, Joffe E, Yi S, Zinzani PL, Tedeschi A, Nishimura N, Lemech CR, Bussolari J, Deng C, Assefa AT, Van Hemelryck S, Snoeys J, Hodkinson BP, Fourneau N, Cao Y, Srinivasan S, Guo Y, Soete V, Soriano Paradinas I, Fontan L, Philippar U, Gerecitano JF, Morschhauser F.
Blood cancer discovery · 2026-09-30 · PMID 42814116

文献摘要

Following preclinical findings, we evaluated safimaltib (MALT1 protease inhibitor; JNJ-67856633) in relapsed/refractory B-cell non-Hodgkin lymphomas or chronic lymphocytic leukemia in a multi-center, phase-1, dose-escalation/dose-expansion study (NCT03900598). Primary endpoints were recommended phase-2 dose (RP2D) and safety. Among 226 patients, 56.2% had diffuse large B-cell lymphoma (DLBCL); 47.3% received ≥4 prior therapy lines. RP2D was once-daily, 300-mg, oral safimaltib±loading dose. Most common adverse events (AEs) were hyperbilirubinemia (48.2%; off-target related), anemia (36.7%), neutropenia (31.4%), and thrombocytopenia (27.4%). Dose reduction mitigated safimaltib-related AEs. Objective response rate was 28.8% (95% CI: 23.0%-35.1%), including 9 (3.9%) complete responses. All patients with non-germinal-center B-cell-like DLBCL and ≥1 B-cell-receptor pathway activating mutation (n=5) responded to safimaltib. Safimaltib exhibited on-target activity in translational studies, affecting NF-κB-regulated cytokines. Proof-of-principle activity in this first MALT1-targeting study in hematologic malignanices suggest MALT1 may be a feasible target in humans and supports further investigation despite observed off-target effects.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。